SEC Tracker
Get the app

Connect Biopharma Holdings CNTB

Connect Biopharma Holdings Q2 FY25: revenue $48K; diluted EPS −$0.23

Form
10-Q
Filed
Period
Importance
Notable
Document
10-Q
Exhibit 10.1
Material contract

Key figures from this report

These are the numbers Connect Biopharma Holdings reported for Q2 FY25, the quarter ended Jun 30, 2025, as tagged in the filing’s XBRL data, each against the same quarter a year earlier. A plain-English reading of this report is not written yet.

  1. Revenue$48KNo year-earlier figure tagged10-Q income statement, on EDGAR
  2. Net income−$12.9MNo year-earlier figure tagged10-Q income statement, on EDGAR
  3. Diluted EPS−$0.23No year-earlier figure tagged10-Q income statement, on EDGAR
  4. Cash and cash equivalents$40.6MNo year-earlier figure taggedCash and equivalents only; the company page adds short-term investments.10-Q balance sheet, on EDGAR
  5. Cash from operations−$12.6MNo year-earlier figure tagged10-Q cash flow statement, on EDGAR; the filing reports year-to-date cash flows; this quarter is the year-to-date total less the earlier quarters

Every quarter in the financial tables

View on EDGAR

Open in the app

Get an email when Connect Biopharma Holdings files

Only major filings: results, leadership changes, listing notices and other major events, each with the plain-English summary when we have one or the key facts and the EDGAR link. Routine insider filings never email. Confirm once; unsubscribe in one click.

Similar companies

Companies of similar size in SIC 2834 and related industry codes: the same peer list as the financial tables.

  1. CervoMed CRVO public float $40M, Jun 30, 2025
  2. Actuate Therapeutics ACTU public float $42M, Jun 30, 2025
  3. Atara Biotherapeutics ATRA public float $39M, Jun 30, 2025
  4. Lite Strategy LITS public float $43M, Dec 31, 2025
  5. BriaCell Therapeutics BCTX public float $37M, Jan 30, 2026